Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

What happened

Adicet Bio granted a new hire non-qualified stock option on October 30, 2026, to buy 1,500 shares at $3.42 per share, the closing price that day. One-fourth vests after one year, with the rest vesting monthly over three years.

Confirmed

Global impact / market context

Stock options pay off only if the share price rises above $3.42, so the new hire gains most if Adicet's shares climb. The small size limits cost to existing owners, who face modest dilution, that is, a slightly smaller share of the company.

Analyst inference

Adicet is a clinical stage biotechnology company, meaning its therapies are still being tested rather than sold. Such companies often pay new staff partly in stock to conserve cash. The grant uses the 2022 Inducement Plan, a pool outside the stockholder-approved plans.

Analyst inference

What to watch

1. The option was granted outside Adicet's stockholder-approved equity incentive plans under its 2022 Inducement Plan, which the board adopted in January 2022 and amended in January 2023. Confirmed
2. Watch future filings for more inducement grants, since relying on this outside-the-plan pool for new hires could raise questions about how much stock-based pay avoids a shareholder vote. Analyst inference
3. Watch whether Adicet's share price moves above $3.42, because the option only delivers value to the employee if the stock rises past that exercise price. Analyst inference

Evidence

• Original source link unavailable